TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01050777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00520598
Drug: Comparator: V505 formulation 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
Study: NCT00520598
Drug: Comparator: V505 formulation 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
Study: NCT03783910
Drug: GRT9906
Approvals — FDA: no, EMA: no, PMDA: no
Description: One prolonged-release tablet containing 40 mg of GRT9906
Study: NCT03783910
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GRT9906 tablets
Study: NCT03348514
Drug: CPX-POM - 30 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-POM
Study: NCT03348514
Drug: CPX-POM - 60 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-POM
Study: NCT03348514
Drug: CPX-POM - 120 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-POM
Study: NCT03348514
Drug: CPX-POM - 240 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-POM
Study: NCT03348514
Drug: CPX-POM - 360 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPX-POM
Study: NCT02580058
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
Study: NCT02293681
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
Study: NCT02803216
Drug: standard triple region
Approvals — FDA: no, EMA: no, PMDA: no
Description: ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
Study: NCT01906840
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02120417
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
Study: NCT02120417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg matching placebo tablets to be administered by mouth
Study: NCT02278978
Drug: BIBF1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBF1120 200 mg two times per day orally
Study: NCT00548912
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03069638
Drug: Sedatives/Hypnotics,Other
Normalized name: SEDATIVES/HYPNOTICS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
Study: NCT00319163
Drug: levonorgestrel/ethinyl estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479466
Drug: MK0893
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Study: NCT00479466
Drug: Placebo to MK0893
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.
Study: NCT02534337
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
Study: NCT03803215
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
Study: NCT01373554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mig/bid or 60mg/bid P.O
Study: NCT00327444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
Study: NCT02047552
Drug: IV iron placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL normal saline
Study: NCT01820910
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
Study: NCT04312997
Drug: PUL-042 Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.3 µg Pam2 : 29.8 µg ODN/mL (50 µg PUL-042)
Study: NCT04312997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline for inhalation
Study: NCT01634243
Drug: SPM 962
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Study: NCT03119649
Drug: GLPG2222 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet(s) containing GLPG2222
Study: NCT03119649
Drug: GLPG2222 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet(s) containing GLPG2222
Study: NCT03119649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral tablet(s) containing placebo
Study: NCT03119649
Drug: GLPG2222 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet(s) containing GLPG2222
Study: NCT03119649
Drug: GLPG2222 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet(s) containing GLPG2222
Study: NCT03469310
Drug: Acetaminophen 500Mg Cap
Normalized name: ACETAMINOPHEN 500MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-narcotic medication first with narcotic as second choice
Study: NCT03469310
Drug: Tylenol #3 Oral Tablet
Normalized name: Tylenol #3 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic medication first
Study: NCT00276289
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03121690
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml saline / day for 7 days
Study: NCT01586091
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02471963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01199341
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg per oral, twice daily for 14 days
Study: NCT01199341
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 100 mg per oral, twice daily for 14 days
Study: NCT03690791
Drug: MediCabilis CBD Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of CBD: \<2mg of THC in one ml. The cannabis oil consists of CBD extract in MCT oil.
Study: NCT03690791
Drug: Placebo Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will contain only hemp seed oil.
Study: NCT00735332
Drug: TLN-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
Study: NCT02001012
Drug: Artemether-lumefantrine combination
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02287246
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mL
Study: NCT00770861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets, oral administration
Study: NCT00662155
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02621333
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
Study: NCT04278573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 ml injection of sterilized sesame oil with no active study ingredient
Study: NCT04011150
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study: NCT03466268
Drug: Gumarontinib Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
Study: NCT01524289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral tablet once daily for 52 weeks
Study: NCT03331211
Drug: TKIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib combined with Chematherapy
Study: NCT02985801
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Capsule
Study: NCT02981212
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination with Mycophenolate Mofetil
Study: NCT02981212
Drug: ARB
Normalized name: Arbli
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
Study: NCT00608465
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg x 1 week followed by 10 mg x 9 weeks.
Study: NCT00267254
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02782481
Drug: ND0612
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02782481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00377962
Drug: Mycophenolic acid (MPA)/azathioprine (AZA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
Study: NCT00377962
Drug: Calcineurin inhibitors (CNI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
Study: NCT00377962
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
Study: NCT00374556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3mg placebo capsule, once daily at bedtime
Study: NCT03269591
Drug: diclofenac tablets
Normalized name: diclofenac Oral Tablet
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drugs
Study: NCT03653429
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered prior to surgical incision
Study: NCT00403546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
Study: NCT00723658
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01939366
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be matched to pregabalin and cebranopadol.
Study: NCT02551172
Drug: HCP1105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin + Omega-3-acids ethyl esters
Study: NCT02551172
Drug: HGP0816
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin
Study: NCT02551172
Drug: Placebo of HCP1105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean Oil
Study: NCT02551172
Drug: Placebo of HGP0816
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusion of Rosuvastatin in HGP0816
Study: NCT01154101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Study: NCT00432198
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT01613092
Drug: Incremental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
Study: NCT01655407
Drug: Autologous Engineered Skin Substitute
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total burn wound area covered will range from 288 cm\^2 to 5,600 cm\^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place.
Study: NCT04691726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus i.v. + continuous i.v. infusion
Study: NCT04075643
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-385 Tab. 1 Tab., single oral administration under fasting condition
Study: NCT04269551
Drug: BIVV020
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:solution for injection Route of administration: intravenous
Study: NCT01802944
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00917384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
Study: NCT00087620
Drug: XELODA [capecitabine]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00467844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01651923
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
Study: NCT00358163
Drug: PTK787/ZK 222584
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken in tablet form daily
Study: NCT00756002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
Study: NCT01879020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (TA-8995 1mg)
Study: NCT01879020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (TA-8995 2.5mg)
Study: NCT01879020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (TA-8995 5mg)
Study: NCT01879020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (TA-8995 10mg)
Study: NCT01879020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (TA-8995 25mg)
Study: NCT03038022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00635102
Drug: D-Cycloserine PO and Glycine IV
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
Study: NCT00635102
Drug: Placebo D-Cycloserine PO and placebo Glycine IV
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT00635102
Drug: Placebo D-Cycloserine PO and Glycine IV
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00635102
Drug: D-Cycloserine PO and placebo Glycine IV
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02105558
Drug: Combined spinal and epidural anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
Study: NCT00651040
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
Study: NCT00631319
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04562337
Drug: SHR1316
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-L1 antibody
Study: NCT02162979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01720251
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections of placebo on days 1, 7, 14, 28 and 56
Study: NCT01720251
Drug: AllerT full dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
Study: NCT01043640
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
Study: NCT01043640
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
Study: NCT01912118
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
Study: NCT03592862
Drug: HTL0018318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT03592862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00881205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
Study: NCT00608140
Drug: Optimal medical therapy (OMT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
Study: NCT02389881
Drug: TAK-058 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-058 placebo-matching solution
Study: NCT04231981
Drug: INCMGA0012
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.
Study: NCT01329757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a subcutaneously injected daily dose of placebo for 1 year
Study: NCT02521246
Drug: Candesartan + Chlorthalidone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02521246
Drug: Losartan+hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03676309
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
Study: NCT02167061
Drug: DA-1229_01 fed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00637728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension, 5 mL once daily
Study: NCT00509106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Study: NCT00251069
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00893607
Drug: NRL001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg NRL001 was administered as a slow release suppository
Study: NCT00183560
Drug: Antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
Study: NCT00551707
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone (2.7 mg)
Study: NCT00551707
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01873950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01905735
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
Study: NCT01364467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.